Medindia

X

The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference

Wednesday, November 5, 2008 General News J E 4
Advertisement
CHICAGO, Nov. 4 The Female Health Company(Amex: FHC) today announced that O.B. Parrish, the Company's Chief ExecutiveOfficer, and Donna Felch, Chief Financial Officer, will present at the Rodman& Renshaw 10th Annual Global Investment Conference at 9:55 a.m. Eastern Timeon November 11, 2008. The Conference is being held at the New York PalaceHotel in New York City.

A live audio webcast of the presentation will be available and archivedfor replay at http://www.wsw.com/webcast/rrshq14/fhc.

About The Female Health Company

The Female Health Company (FHC), headquartered in Chicago, IL, is themaker of the FC Female Condom (FC1 and FC2), a revolutionary option offeringwomen dual protection against both sexually transmitted diseases, includingHIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company inFebruary 1996 with the purchase of Chartex Resources Ltd., the holder ofexclusive worldwide rights to FC1. The Company holds exclusive product andtechnology patents for FC1 in the United States, Australia, Brazil, Canada,France, Germany, Italy, Spain, the United Kingdom, the People's Republic ofChina, South Korea and Japan. Patents are pending for FC2. FHC is the solemanufacturer and marketer of the FC1 and FC2 female condoms in the world. TheFemale Health Company and its partners currently market the Female Condomunder FC Female Condom(R), FC2 Female Condom(R), Reality(R), Femidom(R),Femy(R), and Care(R) in the rest of the world.

For more information about the Female Health Company visit the Company'swebsite at http://www.femalehealth.com and http://www.femalecondom.org. Ifyou would like to be added to the Company's e-mail alert list, please send ane-mail to FHCInvestor@femalehealthcompany.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Actof 1995:

The statements in this release which are not historical fact are"forward-looking statements" as that term is defined in the Private SecuritiesLitigation Reform Act of 1995. Forward-looking statements in this release maybe identified by the use of forward-looking words or phrases such as"anticipate," "believe," "could," "expect," "intend," "may," "planned,""potential," "should," "will," "would" or the negative of those terms or otherwords of similar meaning. These statements are based upon the Company'scurrent plans and strategies, and reflect the Company's current assessment ofthe risks and uncertainties related to its business, and are made as of thedate of this release. The Company assumes no obligation to update anyforward-looking statements contained in this release as a result of newinformation or future events, developments or circumstances. Suchforward-looking statements are inherently subject to known and unknown risksand uncertainties. The Company's actual results and future developments coulddiffer materially from the results or developments expressed in, or impliedby, these forward-looking statements. Factors that may cause actual resultsto differ materially from those contemplated by such forward-lookingstatements include, but are not limited to, the following: product demand andmarket acceptance; competition in the Company's markets and the risk of newcompetitors and new competitive product introductions; the Company's relianceon its international partners in the consumer sector and on the level ofspending on the female condom by country governments, global donors and otherpublic health organizations in the global public sector; the economic andbusiness environment and the impact of government pressures; risks involved indoing business on an international level, including currency risks, regulatoryrequirements, political risks, export restrictions and other trade barriers;the Company's production capacity; efficiency and supply constraints; andother risks detailed in the Company's press releases, shareholdercommunication and Securities and Exchange Commission filings, including theCompany's Form 10-KSB for the fiscal year ended September 30, 2007. Actualevents affecting the Company and the impact of such events on the Company'soperations may vary from those currently anticipated.

SOURCE The Female Health Company
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
OncologyRx Care Advantage(TM) Specialty Pharmacy P...
S
Perrigo Company Announces Dividend Increase